Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 18/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL804935 | 0.89 | S1PR1 (0.46) | S1PR1NPC1ALDH1A1LMNATP53 | |
| SCHEMBL804654 | 0.89 | S1PR1 (0.42) | S1PR1NPC1ALDH1A1LMNATP53 | |
| SCHEMBL804321 | 0.88 | S1PR1 (0.52) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL10269631 | 0.86 | S1PR1 (0.64) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL804680 | 0.85 | S1PR1 (0.48) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL804599 | 0.85 | S1PR1 (0.45) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL10270174 | 0.84 | S1PR1 (0.52) | S1PR1 | |
| SCHEMBL772041 | 0.72 | S1PR1 (0.78) | S1PR1 | |
| SCHEMBL771816 | 0.72 | S1PR1 (0.73) | S1PR1NPC1ALDH1A1LMNATP53 | |
| SCHEMBL774221 | 0.71 | S1PR1 (0.70) | S1PR1NPC1ALDH1A1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071460-A1 | PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS | MERCK SERONO SA (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071460-A1 | PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885NPC1 734/4885ALDH1A1 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.